Skip to main content
Equibles
OMER logo

OMER · Omeros Corp · Webcasts, Transcripts & Audio

Track OMER — free

Use OMER with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OMER.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.88 -0.16 (-0.84%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
72.39M
Volume · Oct 1 1.24M Avg daily vol (3M) 1.77M

Omeros Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Omeros Corp (OMER), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$33.46M '25 Q1 25-05-15 · $ −$25.42M '25 Q2 25-08-14 · $9.89M $56.06M '26 Q1 26-05-13 LATEST · $28.53M $13.23M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Omeros Corp (OMER) Q2 2026 Earnings Call Transcript
Positive tone Yartemlia/narsoplimab commercial momentum Competition from C5 inhibitors Novo Nordisk inventory reimbursement
Revenue
$28.53M
Diluted EPS
$0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-06-18
Omeros Corp (OMER) June 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Omeros Corp (OMER) Q1 2026 Earnings Call Transcript
Confident tone Yartemlia Launch and Commercial Uptake Reimbursement and CMS Coding Novo Nordisk / Zaltanabar Transaction
Revenue
$9.89M
Diluted EPS
$0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Omeros Corp (OMER) Q4 2025 Earnings Call Transcript
Confident tone Yartemlia / narsoplimab FDA approval and launch Novo Nordisk / Zaltenabar deal Transplant center formulary / P&T committee adoption
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Omeros Corp (OMER) Q3 2025 Earnings Call Transcript
Confident tone Yartemlia (narsoplimab) FDA Approval and Commercial Launch Operating Expenses and 2026 Outlook Novo Nordisk Asset Purchase Deal (sultanobar/MASP-3)
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Omeros Corp (OMER) Q2 2025 Earnings Call Transcript
Confident tone Narsoplimab BLA review and PDUFA Commercial launch readiness Balance sheet restructuring and financing
Revenue
$
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Omeros Corp (OMER) Q1 2025 Earnings Call Transcript
Positive tone Narsoplimab FDA approval and launch Zaltenibart PNH program Balance sheet and liquidity management
Revenue
$
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Omeros Corp (OMER) Q4 2024 Earnings Call Transcript
Confident tone Narsoplimab BLA resubmission for TA-TMA Zaltenibart and OMS1029 pipeline European MAA submission
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Omeros Corp (OMER) Q3 2024 Earnings Call Transcript
Positive tone Zaltenibart (OMS906) Phase 2/3 Development Phase 3 Study Design and Enrollment OMIDRIA Commercial Expansion
Diluted EPS
$-0.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Omeros Corp (OMER) Q2 2024 Earnings Call
Diluted EPS
$-0.97
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript
Positive tone OMS906 PNH clinical program Narsoplimab BLA / FDA resubmission OMIDRIA royalty / financial results
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Omeros Corp (OMER) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Omeros Corp (OMER) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Omeros Corp (OMER) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Omeros Corp (OMER) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Omeros Corp (OMER) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Omeros Corp (OMER) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Omeros Corp (OMER) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Omeros Corp (OMER) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Omeros Corp (OMER) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Omeros Corp (OMER) Q3 2021 Earnings Call Transcript
Revenue
$30.00M
▲ 14.9% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Omeros Corp (OMER) Q2 2021 Earnings Call Transcript
Revenue
$28.82M
▲ 113% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Omeros Corp (OMER) Q1 2021 Earnings Call Transcript
Revenue
$21.06M
▼ 10.5% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Omeros Corp (OMER) Q4 2020 Earnings Call Transcript
Revenue
$10.63M
▼ 68.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Omeros Corp (OMER) Q3 2020 Earnings Call Transcript
Revenue
$26.11M
▼ 12.5% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Omeros Corp (OMER) Q1 2020 Earnings Call Transcript
Revenue
$23.54M
▲ 8.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Omeros Corp (OMER) Q4 2019 Earnings Call
Revenue
$33.42M
▲ 51.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1285819 CUSIP 682143102 13F (30d) 3 filings 3 filers Visit website Investor relations